United Health Products, Inc. filed its Form 10-Q quarterly report for the period ended September 30, 2026 with the SEC on November 17, 2026, disclosing continued operating losses and a stockholders' deficit.
Key Highlights
- Net loss for the three months ended September 30, 2026: $(185,268), compared to $(296,459) for the same period in 2025, according to the filing.
- Net loss for the nine months ended September 30, 2026: $(785,250), compared to $(2,150,775) for the nine months ended September 30, 2025.
- Total assets as of September 30, 2026: $204,498, down from $316,698 at December 31, 2025.
- Total stockholders' deficit: $(4,561,713) at September 30, 2026, compared to $(3,984,972) at December 31, 2025.
- Accumulated deficit: $(82,264,062) as of September 30, 2026.
- Shares issued and outstanding: 263,685,588 as of September 30, 2026, per the balance sheet.
- Revenues for both three- and nine-month periods: $0 in 2026 and $0 in 2025, as reported in the statements of operations.
United Health Products Reports Zero Revenue and Widening Deficit in Third Quarter 2026
United Health Products, Inc. (OTC:UEEC), a Nevada-incorporated smaller reporting company headquartered in Darien, Connecticut, reported no revenues for either the three or nine months ended September 30, 2026, consistent with its prior-year periods, according to the quarterly filing. The company disclosed total operating expenses of $150,818 for the three months ended September 30, 2026, comprised of $148,135 in selling, general and administrative expenses and $2,683 in research and development costs.
The filing shows that cash and cash equivalents fell to $5,588 at September 30, 2026, from $65,249 at December 31, 2025. Net cash used in operating activities for the nine months ended September 30, 2026 was $(416,627), compared to $(633,815) for the same period in 2025. Total liabilities stood at $4,766,211 at September 30, 2026, up from $4,301,670 at December 31, 2025, with convertible notes payable, net of debt discount, reported at $1,468,736.
During the nine months ended September 30, 2026, the company issued shares through several transactions. According to the statement of stockholders' deficiency, 895,335 shares were issued for conversion of a convertible note payable, 2,000,000 shares were sold in the second quarter raising $100,674, and an additional 1,900,000 shares were sold in the third quarter for proceeds of $71,563. The company also recognized a gain on derivative liabilities of $56,719 for the nine-month period. The balance sheet reflects that the company carries patents, net of amortization, at $21,262, and deferred offering costs of $155,854.
What Was Disclosed
United Health Products filed its unaudited quarterly report covering the three and nine months ended September 30, 2026, disclosing zero revenues, a net loss of $785,250 for the nine-month period, total assets of $204,498, and a total stockholders' deficit of $(4,561,713) as of the quarter's end.



Please wait processing your request...